Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants

Summary

In patients with lupus anticoagulants (LA), acquired resistance to activated protein C (APC) is difficult to demonstrate with clot-based assays due to the presence of the anticoagulant. Via the conversion of a fluorogenic substrate (thrombinography), we monitored the complete process of thrombin formation and decay and its delimitation by the protein C system in eight consecutive LA-patients without anticoagulant therapy and non-carriers of the V Leiden polymorphism. Thrombin generation was triggered in platelet-poor and platelet-rich plasma by recalcification in the presence of a low concentration of tissue factor.

In 7 out of 8 patients we observed a long lag-time before the thrombin burst (LA effect) together with a marked inability of APC to diminish the thrombin activity. The lag-phase was however prolonged to some degree by APC. The effects were more outspoken in the presence of phospholipids from patients' platelets than with added phospholipids.

Thrombinography thus demonstrates APC resistance in LA-patients despite the occurrence of long lag-times (clotting times). The amount of thrombin activity generated in the presence of APC could be a better indicator of the thrombotic risk than the moment at which the thrombin burst starts.

Keywords

Lupus anticoagulant - acquired APC resistance - thrombin activity - platelets

• References

• 1 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
• 2 Roubey RAS, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997; 350: 1491-3.
• 3 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
• 4 Izumi T, Pound ML, Su Z, Iverson GM, Ortel TL. Anti-β₂-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of β₂-glycoprotein I to phospholipids. Thromb Haemost 2002; 88: 620-6.
• 5 Esmon NL, Smirnov MD, Safa O, Esmon CT. Lupus anticoagulants, thrombosis and the protein C system. Haematologica 1999; 84: 446-51.
• 6 Male C, Mitchell L, Julian J, Vegh P, Joshuan P, Adams M, David M, Andrew ME. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 844-9.
• 7 Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y. Acquired activated protein C resistance is associated with the co-existence of anti-pro-thrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118: 577-83.
• 8 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
• 9 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-603.
• 10 Hezard N, Cornillet P, Droulle C, Gillot P, Potron G, Nguyen P. Factor V Leiden: detection in whole blood by ASA PCR using additional mismatch in antepenultimate position. Thromb Res 1997; 88: 59-66.
• 11 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 12 Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 589-91.
• 13 Regnault V, De Maistre E, Geschier C, Briquel ME, André E, Stoltz JF, Lecompte T. A new fast one-step immunopreparation for activated protein C. Thromb Haemost 1995; 73: 1365
• 14 Wielders S, Mukherjee M, Michiels J, Rijkers DTS, Cambus JP, Knedel RWC, Kakkar V, H.C H, Béguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
• 15 Carson CW, Comp PC, Rezaie AR, Esmon NL, Esmon CT. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol 2000; 27: 384-90.
• 16 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
• 17 Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506 Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
• 18 Derksen RHWM, De Groot PG. Do we know which patients with the antiphospholipid syndrome should receive long-term high dose anticoagulation?. J Autoimmun 2000; 15: 255-9.
• 19 Wahl DG, Bounameaux H, De Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arch Intern Med 2000; 160: 2042-8.